Trial Profile
Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given to Healthy Subjects in Vietnam
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2018
Price :
$35
*
At a glance
- Drugs Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.